Recently it was demonstated that activation of receptor tyrosine kinases HGF/MET mediated resistance to MEKi in MPNST, and points towards a useful combination of MEK and MET inhibition NF1 patients with MPNST [5]. The gene discussed is HGF; the disease is malignant peripheral nerve sheath tumor.